News Articles

Takeda Reports Results for Three Quarters (April-December) of FY2015, Reaffirms Management Guidance for the Full Year OSAKA, Japan -Thursday 4 February 2016

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502): Results of April to December period reaffirms full-year management guidance Underlying revenue +3.8% year-to-year (reported revenue growing +4.0% to 1,393.3 billion yen), led by strong performance in the U.S. and the...

European Commission Approves Label Variation for ADCETRIS® (Brentuximab Vedotin) to Include Data on Retreatment of... -Sunday 24 January 2016

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma...

Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases -Tuesday 12 January 2016  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Ltd. (TOKYO:4502) and enGene, Inc. today announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGene’s “Gene Pill” gene delivery platform. The strategic...

Takeda to Present at the 34th Annual J.P. Morgan Healthcare Conference -Friday 8 January 2016

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO: 4502) ("Takeda") today announced that Christophe Weber, President and Chief Executive Officer of Takeda, will make a formal presentation on January 12, local time, at the 34th Annual J.P. Morgan Healthcare Conference held in San...

Takeda Acquires U.S. Biologics Manufacturing Facility -Wednesday 6 January 2016

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc (NYSE:BXLT). Takeda intends to use the facility primarily for the manufacture...

Takeda Provides Further Information about Its New Business Venture with Teva -Monday 28 December 2015  

(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) today made the below follow-up announcement regarding the overview of their new business venture in Japan, which was initially disclosed on November 30, 2015 in...